Dual HER2 inhibition and paclitaxel in metastatic breast cancer

被引：0
|
作者：
Brower, Vicki
机构：
来源：
LANCET ONCOLOGY | 2015年 / 16卷 / 02期
关键词：
D O I：
10.1016/S1470-2045(14)71201-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E57 / E57
页数：1
相关论文
共 50 条
  • [1] Dual inhibition of HER2 in breast cancer treatment
    Gnant, Michael
    Steger, Guenther G.
    LANCET, 2012, 379 (9816): : 596 - 598
  • [2] Dual HER2 Blockade Slows Metastatic Breast Cancer
    Bender, Eric
    CANCER DISCOVERY, 2012, 2 (01)
  • [3] Inhibition of HER2/β-catenin signaling by penfluridol overcomes resistance to paclitaxel in breast cancer
    Gupta, Nehal
    Gupta, Parul
    Srivastava, Sanjay
    CANCER RESEARCH, 2017, 77
  • [4] Efficacy of HER2 inhibitors in metastatic breast cancer by discordance in HER2 amplification status between primary and metastatic breast cancer
    Van Raemdonck, E.
    Berteloot, P.
    Laenen, A.
    Han, S.
    Van Nieuwenhuysen, E.
    Salihi, R.
    Concin, N.
    Vergote, I.
    Floris, G.
    Wildiers, H.
    Punie, K.
    Neven, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer
    Bidard, F. -C.
    Ng, C. K. Y.
    Cottu, P.
    Piscuoglio, S.
    Escalup, L.
    Sakr, R. A.
    Reyal, F.
    Mariani, P.
    Lim, R.
    Wang, L.
    Norton, L.
    Servois, V.
    Sigal, B.
    Vincent-Salomon, A.
    Weigelt, B.
    Pierga, J. -Y.
    Reis-Filho, J. S.
    ANNALS OF ONCOLOGY, 2015, 26 (08) : 1704 - 1709
  • [6] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [7] Dual HER2 inhibition
    Landman, Allison
    LANCET ONCOLOGY, 2023, 24 (07): : 724 - 724
  • [8] Somatic mutations of the HER2 in metastatic breast cancer
    Fang, Yi
    Jiang, Yanxia
    Wang, Xin
    Yang, Xue
    Gao, Yinqi
    Wang, Jing
    TUMOR BIOLOGY, 2014, 35 (12) : 11851 - 11854
  • [9] Lapatinib in combination with paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2
    Giordano, Sara B.
    Kaklamani, Virginia
    BREAST CANCER MANAGEMENT, 2013, 2 (06) : 529 - 535
  • [10] A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
    Chalasani, Pavani
    Marron, Marilyn
    Roe, Denise
    Clarke, Kathryn
    Iannone, Maria
    Livingston, Robert B.
    Shan, Joseph S.
    Stopeck, Alison T.
    CANCER MEDICINE, 2015, 4 (07): : 1051 - 1059
12345